Exploring selenoproteins in breast cancer prognosis and treatment.
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
This study is testing whether selenoproteins can help predict outcomes and guide treatment for people with triple-negative breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | National Cancer Institute, Naples Academic / other |
| Locations | 2 sites (Naples, Napoli and 1 other locations) |
| Trial ID | NCT05817227 on ClinicalTrials.gov |
What this trial studies
This multicentric observational study investigates the role of selenoproteins as prognostic markers and potential therapeutic targets in breast cancer, specifically triple-negative breast cancer (TNBC). The study includes both retrospective and prospective components, where tissue microarrays will be prepared from surgical samples of TNBC patients, and plasma samples from healthy subjects and metastatic TNBC patients will be analyzed for selenoprotein expression using ELISA. The aim is to better understand the relationship between selenoproteins and breast cancer outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are women diagnosed with triple-negative breast cancer who have not yet received any drug treatment.
Not a fit: Patients with other types of breast cancer or those currently undergoing treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools and targeted therapies for patients with breast cancer.
How similar studies have performed: While the role of selenoproteins in cancer is being explored, this specific approach in TNBC is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * TNBC breast cancer patients, before any drug treatment * healthy women aged 25-60 Exclusion Criteria: * donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.
Where this trial is running
Naples, Napoli and 1 other locations
- Istituto Nazionale Tumori - Fondazione "G.Pascale", IRCCS — Naples, Napoli, Italy (Recruiting)
- Istituto Nazionale Tumori Regina Elena — Roma, Roma, Italy (Recruiting)
Study contacts
- Principal investigator: Alfredo Budillon, M.D. — IRCCS I.N.T. "G. Pascale"
- Study coordinator: Elena Di Gennaro, PhD
- Email: e.digennaro@istitutotumori.na.it
- Phone: 08117770584
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.